Relationship of amyloid beta, tau, and alpha synuclein in CSF and the clinical manifestations and severity in patients with dementia.

Relationship of amyloid beta, tau, and alpha synuclein in CSF and the clinical manifestations and severity in patients with dementia. - Relationship of amyloid beta, tau, and alpha synuclein in CSF and the clinical manifestations and severity in patients with dementia.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041147

Enrollment

100

Registered

2020-07-20

Start date

2012-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cognitive decline who can undergo cognitive function tests and imaging tests

Exclusion criteria

Exclusion criteria: Patients on strong antithrombotic therapy.

Design outcomes

Primary

Measure	Time frame
To clarify the relationship between the levels of amyloid beta protein, tau protein, and alpha-synuclein in cerebrospinal fluid/blood, clinical disease type, and imaging findings.	—

Secondary

Measure	Time frame
To investigate the correlation between the severity of Alzheimer's disease and dementia with Lewy bodies and the levels of cerebrospinal fluid/blood amyloid beta protein, tau protein, and alpha-synuclein.	—

Countries

Japan

Contacts

Public ContactTadanori Hamano

University of Fukui Second Department of Internal Medicine

hamano@u-fukui.ac.jp0776-61-3111

Outcome results